Vericel to Present at the UBS Virtual Global Healthcare Conference on Wednesday, May 20, 2020

Rhea-AI Summary

Vericel Corporation (NASDAQ: VCEL) will present a company overview at the UBS Virtual Global Healthcare Conference on May 20, 2020, at 12:30 PM Eastern Time. Nick Colangelo, the company's president and CEO, will be leading the presentation. A live webcast will be accessible on Vericel's Investor Relations website for those interested in learning more about the company's advancements in sports medicine and severe burn care. Vericel is recognized for its products, MACI® and Epicel®, and its license for NexoBrid®.

News Market Reaction – VCEL

-2.35%

1 alert

-2.35% News Effect

On the day this news was published, VCEL declined 2.35%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

CAMBRIDGE, Mass., May 13, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the UBS Virtual Global Healthcare Conference.  The conference is being conducted with a virtual format and the presentation will take place on Wednesday, May 20, 2020 at 12:30pm Eastern Time.

A live webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com

About Vericel Corporation
Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets.  The company markets two cell therapy products in the United States.  MACI^® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults.  Epicel^® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area.  The company also holds an exclusive license for North American commercial rights to NexoBrid^®, a registration-stage biological orphan product for debridement of severe thermal burns.  For more information, please visit the company's website at www.vcel.com.

Epicel^® and MACI^® are registered trademarks of Vericel Corporation.  NexoBrid^® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation.  © 2019 Vericel Corporation.  All rights reserved.

Investor Contacts:
Lee Stern
Solebury Trout
lstern@troutgroup.com
+1 646-378-2922

FAQ

When is Vericel Corporation's presentation at the UBS Virtual Global Healthcare Conference?

Vericel Corporation's presentation will take place on May 20, 2020, at 12:30 PM Eastern Time.

Who will present at the UBS Virtual Global Healthcare Conference for Vericel Corporation?

Nick Colangelo, president and CEO, will present at the conference.

How can I access the presentation by Vericel Corporation?

The presentation will be available via live webcast on the Investor Relations section of the Vericel Corporation website.

What products does Vericel Corporation offer?

Vericel Corporation markets MACI® for cartilage repairs and Epicel® for skin replacement in severe burns.

What is the significance of NexoBrid for Vericel Corporation?

Vericel holds an exclusive license for NexoBrid®, which is designed for debridement of severe thermal burns.